Director – LNP Formulation
Kernal Biologics
Director – LNP Formulation
Kernal Biologics
Develops onco-selective mRNA therapeutics
About Kernal Biologics, Inc.
Kernal Bio is a venture-backed therapeutics company engineering cells inside the body using AI-designed, selective mRNA and targeted LNP technology. By developing in vivo CAR-T therapies, Kernal Bio is advancing precision treatments for autoimmune diseases and blood cancers. The company was founded by experts from MIT, Harvard, Merck, and BMS, and its leadership team brings a track record of three FDA-approved therapies and over 120 patents. Based in Boston, the company is backed by Hummingbird Ventures, Amgen, Lilly, HBM, ARPA-H, and NVIDIA. Kernal Bio is transforming the future of cell therapy design and delivery.
Job Summary:
Kernal is seeking an individual with deep expertise in RNA delivery space to lead our mRNA delivery efforts. This person will report to the SVP of R&D and will be responsible for overseeing the development novel LNP (lipid nanoparticle) systems for in vivo mRNA delivery to support our immuno-oncology and immunology efforts. The successful candidate must be able to work in a fast paced and highly dynamic biotech environment. Ideal candidate will be a leader and a great team player with excellent communication skills and effective, inspiring management style.
Responsibilities:
Requirements:
Benefits:
Kernal provides a diverse work environment and is committed to equal employment opportunities for all its employees and qualified applicants. We do not discriminate in employment practices for the race, color, national origin, age, gender, sexual orientation, marital or veteran status, religion, disability, or any other legally protected status. Kernal Bio will make reasonable accommodations for qualified individuals with known disabilities in accordance with applicable law.
Develops onco-selective mRNA therapeutics
Kernal Biologics develops mRNA therapies that target cancer cells and infectious diseases like COVID-19. It uses a proprietary platform that combines synthetic biology and deep learning to design mRNA molecules that avoid triggering RNA-sensing pathways and to enable therapeutic protein expression in specific cell types. The product works by delivering engineered mRNA into target cells, where it instructs them to produce a therapeutic protein with restricted expression to reduce side effects. The company differentiates itself through onco-selectivity, its data-driven design process, and partnerships with healthcare providers, research institutions, and pharmaceutical companies. Revenue comes from collaborations, grants, and sales of its mRNA platforms and therapies. The goal is to provide effective, tolerable, and affordable mRNA medicines by advancing targeted, cell-specific therapies for cancer and infectious diseases.
Explore more opportunities at Kernal Biologics